Prs28 Adherence to Inhaled Corticosteroid Use and Local Adverse Events in Persistent Asthma

Ivanova, Jasmina; Yu, AP; Birnbaum, HG; Hsieh, Matthew M.; Seal, Brian; Molen, Thys van der; Emani, Sirisha; Rosiello, Richard; Colice, Gene

doi:10.1016/s1098-3015(10)70876-7

Cited by 25 publications

(51 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another study involving 1410 patients with persistent asthma showed that 20.7% of them were highly adherent to inhaled corticosteroids therapy 19 . These rates are considerably lower than the 60% reported by Demoly et al in a community-based survey that involved five European countries 20 .…”

Section: Discussionmentioning

confidence: 99%

Evaluation of factors affecting adherence to asthma controller therapy in chest clinics in a sub-Saharan African setting: a cross-sectional study

et al. 2016

View full text Add to dashboard Cite

Abstract:Background: Adherence to controller therapy in asthma is a major concern during the management of the disease. Objective: To determine the adherence rate and identify the predictors of low adherence to asthma controller therapy. Methods: A cross-sectional study including asthma patients was conducted from November 1, 2012 to May 31, 2013 in 4 chest clinics in Cameroon. The adherence to asthma treatment was rated using Morisky Medication Adherence Scale. A multivariate logistic regression analysis was performed for the identification of factors associated with adherence to asthma treatment. Results: Among the 201 asthma patients included, 133 (66.2%) were female. The mean age of participants was 41.2 years. Sixty-one (30.3%) of the patients did not visit the chest physician during the last year prior to the study. Asthma was well controlled in 118 patients (58.7%). The prevalence of low adherence rate to asthma controller therapy was 44.8% and the absence of any chest specialist visit within the last 12 months was the only factor associated with the low adherence rate to asthma treatment (OR 5.57 ; 95% CI 2.84-10.93). Conclusion:The adherence rate to asthma controller therapy in Cameroon is low and it could be improved if scheduled visits are respected by patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of factors affecting adherence to asthma controller therapy in chest clinics in a sub-Saharan African setting: a cross-sectional study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The other measure of self-reported adherence used was a visual analogue scale, which asks patients to put a line on a 10-cm scale indicating how much of the time they use all of their glaucoma medications exactly as directed (range is from 0 ¼ none of the time to 10 ¼ all of the time). [39][40][41][42][43] The visual analogue scale has strong validity and reliability. [39][40][41][42][43] Forty-three packets were returned for a response rate of 72%.…”

Section: Discussionmentioning

confidence: 99%

“…[39][40][41][42][43] The visual analogue scale has strong validity and reliability. [39][40][41][42][43] Forty-three packets were returned for a response rate of 72%. Table 1 presents the patient characteristics.…”

Section: Discussionmentioning

confidence: 99%

Development of an instrument to measure glaucoma medication self-efficacy and outcome expectations

Sleath

Blalock

Robin

et al. 2009

Eye

View full text Add to dashboard Cite

Purpose The purpose of this study was to develop and evaluate the psychometric properties of (a) a glaucoma medication selfefficacy scale and (b) a glaucoma outcome expectations scale.Patients and Methods Two instruments were developed: a glaucoma medication selfefficacy scale and a glaucoma outcome expectations scale. Packets containing (a) the instruments and patient demographic questions and (b) a letter explaining the study were distributed to 225 glaucoma patients from three ophthalmology practices between August and December 2007. The instrument was completed by 191 patients for a response rate of 85%. Principal components factor analysis with a varimax rotation and Cronbach's a reliability were used to analyse the data. To assess discriminant validity, we administered the scales and two self-reported measures of adherence in a separate sample of 43 glaucoma patients who were currently using at least one glaucoma medication.Results Our results yielded a 21-item self-efficacy in overcoming barriers that might interfere with the use of glaucoma medications scale, a 14-item self-efficacy in carrying out specific tasks required to use eye drops correctly scale, and a four-item glaucoma outcome expectations scale. Results of the Cronbach's a reliability indicated that the scales are internally consistent. The selfefficacy scales were both significantly associated with two patient self-reported measures of glaucoma medication adherence, which show discriminant validity.Conclusions Eye care providers and researchers can use these scales to identify patients with low self-efficacy in using their glaucoma medications and patients who do not believe that following their eye care providers' advice can help their vision.

show abstract

“…( 3 , 8 , 10 ) Several factors can affect the fraction of an inhaled dose that is deposited in the oral cavity. These factors include ICS formulation, type of drug delivery system, and patient adherence to the instructions for use.…”

Section: Discussionmentioning

confidence: 99%

“…( 3 , 8 , 10 ) Diversos fatores podem influenciar a proporção de uma dose inalada que é depositada na cavidade orofaríngea. Esses incluem a formulação do CI, o tipo de sistema de liberação do medicamento e a adesão do paciente às instruções para sua administração.…”

Section: Discussionunclassified

Local adverse effects associated with the use of inhaled corticosteroids in patients with moderate or severe asthma

Pinto

Almeida

Marques³

et al. 2013

J. bras. pneumol.

View full text Add to dashboard Cite

OBJECTIVE: To describe and characterize local adverse effects (in the oral cavity, pharynx, and larynx) associated with the use of inhaled corticosteroids (ICSs) in patients with moderate or severe asthma. METHODS: This was a cross-sectional study involving a convenience sample of 200 asthma patients followed in the Department of Pharmaceutical Care of the Bahia State Asthma and Allergic Rhinitis Control Program Referral Center, located in the city of Salvador, Brazil. The patients were ≥ 18 years of age and had been using ICSs regularly for at least 6 months. Local adverse effects (irritation, pain, dry throat, throat clearing, hoarseness, reduced vocal intensity, loss of voice, sensation of thirst, cough during ICS use, altered sense of taste, and presence of oral candidiasis) were assessed using a 30-day recall questionnaire. RESULTS: Of the 200 patients studied, 159 (79.5%) were women. The mean age was 50.7 ± 14.4 years. In this sample, 55 patients (27.5%) were using high doses of ICS, with a median treatment duration of 38 months. Regarding the symptoms, 163 patients (81.5%) reported at least one adverse effect, and 131 (65.5%) had a daily perception of at least one symptom. Vocal and pharyngeal symptoms were identified in 57 (28.5%) and 154 (77.0%) of the patients, respectively. The most commonly reported adverse effects were dry throat, throat clearing, sensation of thirst, and hoarseness. CONCLUSIONS: Self-reported adverse effects related to ICS use were common among the asthma patients evaluated here.

show abstract

Prs28 Adherence to Inhaled Corticosteroid Use and Local Adverse Events in Persistent Asthma

Cited by 25 publications

References 0 publications

Evaluation of factors affecting adherence to asthma controller therapy in chest clinics in a sub-Saharan African setting: a cross-sectional study

Evaluation of factors affecting adherence to asthma controller therapy in chest clinics in a sub-Saharan African setting: a cross-sectional study

Development of an instrument to measure glaucoma medication self-efficacy and outcome expectations

Local adverse effects associated with the use of inhaled corticosteroids in patients with moderate or severe asthma

Contact Info

Product

Resources

About